Using the ‘golden key’ to identify suitable patients, the results from the trial indicate that deaths could be cut by a third ...

The ItovebiTM (inavolisib)-based regimen reduced the risk of death by more than 30% in people with PIK3CA-mutated HR-positive ...

Kamil Scibior, 128 Crossneen Manor, Leighlinbridge was sent to prison for six years after he pleaded guilty to a single count ...

Roche shares new data showing its MS drug fenebrutinib maintained low relapse rates and no disability progression in patients ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

A colorectal cancer drug from Pfizer Inc. doubled survival time compared to the standard of care for a subset of patients, ...

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has ...

Swiss pharmaceutical company Roche has announced that a new antibiotic, zosurabalpin, is progressing to phase 3 testing.

In March, the U.S. Food and Drug Administration (FDA) announced voluntary recalls of several popular acne products due to ...

GSK and Spero Therapeutics’ Phase III trial of their oral antibiotic for complicated urinary tract infections (cUTI) will end ...